Clinical Trial Detail

NCT ID NCT02650401
Title Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors And Primary Cns Tumors, With or Without Trk, Ros1, or Alk Fusions
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Ignyta, Inc.
Indications

neuroblastoma

central nervous system cancer

Advanced Solid Tumor

Therapies

Entrectinib

Age Groups: adult child

Additional content available in CKB BOOST